z-logo
open-access-imgOpen Access
The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae
Author(s) -
Courtney Luterbach,
Ashley Boshe,
Heather Henderson,
Eric Cober,
Sandra S. Richter,
Robert A. Salata,
Robert C. Kalayjian,
Richard Watkins,
Andrea M. Hujer,
Kristine M. Hujer,
Susan D. Rudin,
Tatiana Domitrovic,
Yohei Doi,
Keith S. Kaye,
Scott Evans,
Vance G. Fowler,
Robert A. Bonomo,
David van Duin
Publication year - 2018
Publication title -
open forum infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.546
H-Index - 35
ISSN - 2328-8957
DOI - 10.1093/ofid/ofy351
Subject(s) - carbapenem resistant enterobacteriaceae , medicine , trimethoprim , enterobacteriaceae , carbapenem , sulfamethoxazole , microbiology and biotechnology , pathogenic organism , enterobacteriaceae infections , antibiotics , escherichia coli , biology , biochemistry , gene
In the Consortium on Resistance Against Carbapenems in Klebsiella and other Enterobacteriaceae (CRACKLE), trimethoprim-sulfamethoxazole (TMP-SMX) had a limited role in the treatment of less severe carbapenem-resistant Enterobacteriaceae (CRE) infections, especially urinary tract infections. Of tested CRE, only 29% were susceptible to TMP-SMX. Development of resistance further limits the use of TMP-SMX in CRE infections.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom